Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 6 | 2023 | 193 | 2.660 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2023 | 43 | 1.910 |
Why?
|
| Uterine Neoplasms | 5 | 2023 | 227 | 1.280 |
Why?
|
| Sarcoma, Endometrial Stromal | 3 | 2022 | 8 | 1.270 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 2 | 2022 | 18 | 1.040 |
Why?
|
| Leiomyosarcoma | 2 | 2023 | 40 | 1.040 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2023 | 3 | 0.930 |
Why?
|
| Teratoma | 1 | 2023 | 50 | 0.890 |
Why?
|
| Hair Diseases | 1 | 2022 | 9 | 0.860 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 177 | 0.820 |
Why?
|
| Obstetrics | 1 | 2023 | 120 | 0.790 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 744 | 0.700 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 546 | 0.600 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 1077 | 0.510 |
Why?
|
| Neoplasms | 1 | 2021 | 2898 | 0.270 |
Why?
|
| Female | 12 | 2023 | 44547 | 0.250 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1464 | 0.240 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 43 | 0.230 |
Why?
|
| Adenosarcoma | 1 | 2022 | 3 | 0.220 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2021 | 15 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 19 | 0.210 |
Why?
|
| Neoplasm Grading | 1 | 2023 | 357 | 0.200 |
Why?
|
| Gene Fusion | 1 | 2021 | 38 | 0.200 |
Why?
|
| Buprenorphine | 1 | 2021 | 33 | 0.200 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2021 | 30 | 0.190 |
Why?
|
| Humans | 12 | 2023 | 86658 | 0.190 |
Why?
|
| Estrogen Receptor alpha | 1 | 2021 | 144 | 0.190 |
Why?
|
| beta Catenin | 1 | 2022 | 251 | 0.190 |
Why?
|
| Germ Cells | 1 | 2021 | 126 | 0.180 |
Why?
|
| Sarcoma | 1 | 2021 | 215 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 200 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 336 | 0.160 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 1753 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1938 | 0.160 |
Why?
|
| Physical Conditioning, Animal | 1 | 2016 | 19 | 0.150 |
Why?
|
| Fructose | 1 | 2016 | 35 | 0.150 |
Why?
|
| Ventricular Function | 1 | 2016 | 53 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2022 | 1458 | 0.140 |
Why?
|
| Vasodilation | 2 | 2016 | 96 | 0.130 |
Why?
|
| Algorithms | 1 | 2023 | 1830 | 0.120 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 275 | 0.110 |
Why?
|
| Action Potentials | 1 | 2016 | 573 | 0.100 |
Why?
|
| Aging | 1 | 2016 | 691 | 0.100 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2010 | 11 | 0.100 |
Why?
|
| Angiotensin II | 1 | 2010 | 95 | 0.090 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 81 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2010 | 270 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2010 | 177 | 0.080 |
Why?
|
| Arterioles | 2 | 2016 | 22 | 0.060 |
Why?
|
| Superoxides | 2 | 2016 | 73 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2023 | 33 | 0.060 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2023 | 23 | 0.060 |
Why?
|
| DNA Mismatch Repair | 1 | 2023 | 52 | 0.060 |
Why?
|
| Ribonuclease III | 1 | 2022 | 14 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2023 | 69 | 0.050 |
Why?
|
| Dogs | 2 | 2016 | 686 | 0.050 |
Why?
|
| Nitric Oxide | 2 | 2016 | 278 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 63 | 0.050 |
Why?
|
| Homozygote | 1 | 2022 | 200 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 62 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2022 | 205 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 435 | 0.050 |
Why?
|
| Methadone | 1 | 2021 | 36 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 262 | 0.050 |
Why?
|
| Opiate Substitution Treatment | 1 | 2021 | 30 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 279 | 0.050 |
Why?
|
| Placenta | 1 | 2021 | 175 | 0.050 |
Why?
|
| Recurrence | 1 | 2021 | 1139 | 0.040 |
Why?
|
| RNA | 1 | 2021 | 560 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 720 | 0.040 |
Why?
|
| Shear Strength | 1 | 2016 | 19 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2016 | 45 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 88 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2016 | 125 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2706 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 152 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2016 | 239 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2379 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2380 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2894 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 448 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 450 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 2271 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2016 | 711 | 0.030 |
Why?
|
| Animals | 3 | 2016 | 26590 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Losartan | 1 | 2010 | 42 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 3968 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 3992 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 90 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3361 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 263 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 8495 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 7998 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2010 | 1143 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 25658 | 0.010 |
Why?
|
| Male | 2 | 2016 | 40985 | 0.010 |
Why?
|